In 2018, ONPATTRO®, an LNP that contained a siRNA (siRNA-LNP) against transthyretin, was approved as the first siRNA therapeutic technology for the treatment of hereditary transthyretin-mediated amyloidosis [6]. Here, TTR is linked to amyloidosis.